|
|
|
| Research progress on the mechanism of damage of diabetic kidney disease glomerular filtration barrier caused by lipotoxicity |
| SONG Kaiyong1 XIONG Weijian1 TIAN Lu1 XIONG Mengyuan2 TAO Wenqiang1 WANG Miao1 |
1.Department of Nephropathy, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400010, China;
2.Department of Gastroenterology, Huanggang Traditional Chinese Medicine Hospital, Hubei Province, Huanggang 438000, China |
|
|
|
|
Abstract More than 10% of the population is affected by abnormal kidney function, and most kidney diseases are characterized by a breakdown of the glomerular filtration barrier. Glomerular filtration barrier is a unique multilayered structure composed of glomerular endothelial cells, basement membrane, and podocytes. When lipid metabolism is disturbed, it will induce P2X7R-NLRP3 inflammatory body axis, sterol-regulatory element binding protein, vascular endothelial growth factor-B, junction adhesion molecule-like protein, sterol-O-acyl transferase 1, ATP-binding cassette transporter A1, and other proteases and factors to produce inflammatory response and oxidative stress. This paper focuses on the effects of lipid toxicity caused by ectopic lipid deposition on glomerular filtration barrier, which will provide a new idea for the treatment of diabetic kidney disease.
|
|
|
|
|
|
[1] Butt L，Unnersj?觟-Jess D，H?觟hne M，et al. A molecular mechanism explaining albuminuria in kidney disease [J]. Nat Metab，2020，2（5）：461-474.
[2] Lenoir O，Jasiek M，Hénique C，et al. Endothelial cell and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis [J]. Autophagy，2015，11（7）：1130- 1145.
[3] Suh JH，Miner JH. The glomerular basement membrane as a barrier to albumin [J]. Nat Rev Nephrol，2013，9（8）：470-477.
[4] Bartlett CS，Jeansson M，Quaggin SE. Vascular growth factors and glomerular disease [J]. Annu Rev Physiol，2016，78：437-461.
[5] Lin YC，Wang JC，Wu MS，et al. Nifedipine exacerbates lipogenesis in the kidney via KIM-1，CD36，and SREBP upregulation：implications from an animal model for human study [J]. Int J Mol Sci，2020，21（12）：4359.
[6] Tang JJ，Li JG，Qi W，et al. Inhibition of SREBP by a small molecule，betulin，improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques [J]. Cell Metab，2011，13（1）：44-56.
[7] Eberlé D，Hegarty B，Bossard P，et al. SREBP transcription factors：master regulators of lipid homeostasis [J]. Biochimie，2004，86（11）：839-848.
[8] Ruiz S，Pergola PE，Zager RA，et al. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease [J]. Kidney Int，2013，83（6）：1029-1041.
[9] Ghosh A，Gao L，Thakur A，et al. Role of free fatty acids in endothelial dysfunction [J]. J Biomed Sci，2017，24（1）：50.
[10] Murea M，Freedman BI，Parks JS，et al. Lipotoxicity in diabetic nephropathy：the potential role of fatty acid oxidation [J]. Clin J Am Soc Nephrol，2010，5（12）：2373-2379.
[11] Brown MS，Radhakrishnan A，Goldstein JL. Retrospective on cholesterol homeostasis：the central role of scap [J]. Annu Rev Biochem，2018，87：783-807.
[12] Wei Y，Han S，Zhou R，et al. Increased serum VEGF-B level is associated with renal function impairment in patients with type 2 diabetes [J]. Ront Endocrinol（Lausanne），2022，13：862545.
[13] Eremina V，Cui S，Gerber H，et al. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival [J]. J Am Soc Nephrol，2006，17（3）：724-735.
[14] Chen R，Lee C，Lin X，et al. Novel function of VEGF-B as an antioxidant and therapeutic implications [J]. Pharmacol Res，2019，143：33-39.
[15] Hagberg CE，Mehlem A，Falkevall A，et al. Targeting VEGF- B as a novel treatment for insulin resistance and type 2 diabetes [J]. Nature，2012，490（7420）：426-430.
[16] Brosius FC，Coward RJ. Podocytes，signaling pathways，and vascular factors in diabetic kidney disease [J]. Adv Chronic Kidney Dis，2014，21（3）：304-310.
[17] Arjunan P，Lin X，Tang Z，et al. VEGF-B is a potent antioxidant [J]. Proc Nat Acad Sci U S A，2018，115（41）：10351- 10356.
[18] Mohammedi K，Patente TA，Bellili-Mu?觡oz N，et al. Glutathione peroxidase-1 gene （GPX1） variants，oxidative stress and risk of kidney complications in people with type 1 diabetes [J]. Metabolism，2016，65（2）：12-19.
[19] El-Boshy M，Alsaegh A，Qasem AH，et al. Enhanced renoprotective actions of paricalcitol and omega-3 fatty acids co-therapy against diabetic nephropathy in rat [J]. J Adv Res，2021，38：119-129.
[20] Heinonen SE，Kivel?覿 AM，Huusko J，et al. The effects of VEGF-A on atherosclerosis，lipoprotein profile，and lipo- protein lipase in hyperlipidaemic mouse models [J]. Cardiovasc Res，2013，99（4）：716-723.
[21] Dumas SJ，Meta E，Borri M，et al. Phenotypic diversity and metabolic specialization of renal endothelial cells [J]. Nat Rev Nephrol，2021，17（7）：441-464.
[22] Lago-Sampedro A，Lhamyani S，Valdés S，et al. Serum vascular endothelial growth factor b and metabolic syndrome incidence in the population based cohort Di@bet.es study [J]. Int J Obes（Lond），2022，46（11）：2013-2020.
[23] Falkevall A，Mehlem A，Palombo I，et al. Reducing VEGF- B signaling ameliorates renal lipotoxicity and protects aga- inst diabetic kidney disease [J]. Cell Metab，2017，25（3）： 713-726.
[24] Jarad G，Cunningham J，Shaw AS，et al. Proteinuria precedes podocyte abnormalities in Lamb2-/- mice，implicating the glomerular basement membrane as an albumin barrier [J]. J Clin Invest，2006，116（8）：2272-2279.
[25] Haraldsson B，Nystr?觟m J，Deen WM. Properties of the glom- erular barrier and mechanisms of proteinuria [J]. Physiol Rev，2008，88（2）：451-487.
[26] Marshall CB. Rethinking glomerular basement membrane th- ickening in diabetic nephropathy：adaptive or pathogenic? [J]. Am J Physiol Renal Physiol，2016，311（5）：F831-F843.
[27] Datta K，Li J，Karumanchi SA，et al. Regulation of vascular permeability factor/vascular endothelial growth factor （VPF/ VEGF-A） expression in podocytes [J]. Kidney Int，2004， 66（4）：1471-1478.
[28] Kriz W，Lemley KV. A potential role for mechanical forces in the detachment of podocytes and the progression of CKD [J]. J Am Soc Nephrol，2015，26（2）：258-269.
[29] Qin X，Zhao Y，Gong J，et al. Berberine protects glomerular podocytes via inhibiting drp1-mediated mitochondrial fission and dysfunction [J]. Theranostics，2019，9（6）：1698- 1713.
[30] Defronzo RA，Reeves WB，Awad AS. Pathophysiology of diabetic kidney disease：impact of SGLT2 inhibitors [J]. Nat Rev Nephrol，2021，17（5）：319-334.
[31] Qiu YY，Tang LQ. Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy [J]. Pharmacol Res，2016，114：251-264.
[32] Mulay SR. Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases [J]. Kidney Int，2019，96（1）：58-66.
[33] Shahzad K，Fatima S，Khawaja H，et al. Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease [J]. Kidney Int，2022，102（4）：766-779.
[34] Lassén E，Bouchareb R，Daehn IS. Podocyte as the link between sterile inflammation and diabetic kidney disease [J]. Kidney Int，2022，102（4）：688-690.
[35] Zhao J，Wang H，Dai C，et al. P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/caspase 1 pathway [J]. Arthritis Rheum，2013，65（12）：3176-3185.
[36] Solini A，Menini S，Rossi C，et al. The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet：possible role of NLRP3 inflammasome activation [J]. J Pathol，2013，231（3）：342-353.
[37] Turner CM，Vonend O，Chan C，et al. The pattern of distribution of selected ATP-sensitive P2 receptor subtypes in normal rat kidney：an immunohistological study [J]. Cells Tissues Organs，2003，175（2）：105-117.
[38] Rossi C，Santini E，Chiarugi M，et al. The complex P2X7 receptor/inflammasome in perivascular fat tissue of heavy smokers [J]. Eur J Clin Invest，2014，44（3）：295-302.
[39] Niemi K，Teiril?覿 L，Lappalainen J，et al. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway [J]. J Immunol，2011，186（11）：6119-6128.
[40] Vanden Berghe T，Demon D，Bogaert P，et al. Simultaneous targeting of IL-1 and IL-18 is required for protection against inflammatory and septic shock [J]. Am J Respir Crit Care Med，2014，189（3）：282-291.
[41] Haneklaus M，O’Neill LA. NLRP3 at the interface of metabolism and inflammation [J]. Immunol Rev，2015，265（1）：53-62.
[42] Escribá PV，Busquets X，Inokuchi J，et al. Membrane lipid therapy：modulation of the cell membrane composition and structure as a molecular base for drug discovery and new disease treatment [J]. Prog Lipid Res，2015，59：38-53.
[43] Rahman K，Desai C，Iyer SS，et al. Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat，fructose，and cholesterol [J]. Gastroenterology，2016，151（4）：733-746.
[44] Sokeechand BSH，Trigatti BL. Un-JAMming atherosclerotic arteries：JAM-L as a target to attenuate plaque development [J]. Clin Sci（Lond），2019，133（14）：1581-1585.
[45] Kim JJ，Wilbon SS，Fornoni A. Podocyte Lipotoxicity in CKD [J]. Kidney360，2021，2（4）：755-762.
[46] Ducasa GM，Mitrofanova A，Fornoni A. Crosstalk between lipids and mitochondria in diabetic kidney disease [J]. Curr Diab Rep，2019，19（12）：144.
[47] Hai Q，Ritchey B，Robinet P，et al. Quantitative trait locus mapping of macrophage cholesterol metabolism and CRIS- PR/Cas9 editing implicate an ACAT1 truncation as a causal modifier variant [J]. Arterioscler Thromb Vasc Biol，2018， 38（1）：83-91.
[48] Merscher S，Pedigo CE，Mendez AJ. Metabolism，energetics，and lipid biology in the podocyte-cellular cholesterol- mediated glomerular injury [J]. Front Endocrinol（Lausanne），2014，5：169.
[49] Pedigo CE，Ducasa GM，Leclercq F，et al. Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury [J]. J Clin Invest，2016，126（9）：3336-3350.
[50] Guan C，Niu Y，Chen SC，et al. Structural insights into the inhibition mechanism of human sterol O-acyltransferase 1 by a competitive inhibitor [J]. Nat Commun，2020，11（1）：2478.
[51] Diez-Sampedro A，Lenz O，Fornoni A. Podocytopathy in diabetes：a metabolic and endocrine disorder [J]. Am J Kidney Dis，2011，58（4）：637-646.
[52] Merscher-Gomez S，Guzman J，Pedigo CE，et al. Cyclodextrin protects podocytes in diabetic kidney disease [J]. Diabetes，2013，62（11）：3817-3827. |
|
|
|
